The association between bilirubin (BIL) and cardiovascular disease (CVD) remains controversial. We performed a meta-analysis of prospective studies to evaluate this association in the general population. We searched PubMed, EMBASE, Web of Science, Cochrane, and Scopus databases through to September 2021. The Newcastle-Ottawa Quality Assessment Scale was used to assess study quality. The pooled effect estimate was calculated by the fixed-effect model or random-effect model. We included 12 prospective studies (368 567 participants). The pooled risk ratio of CVD for the lowest vs highest groups of BIL levels was .75 (95% CI: .58-.97) with high heterogeneity (I2 = 87.5%, P < .001). Similar associations were observed for coronary heart disease and stroke. We further performed a “dose-response” meta-analysis, and a significant U-shaped relationship between circulating (most values were serum bilirubin, but a few were plasma bilirubin) BIL and CVD (P < .01) was observed. The lowest risk of CVD events was observed in participants with a BIL of 17-20 µmol/L in serum and/or plasma. In conclusion, there was a U-shaped dose-response relationship between BIL and CVD, especially for men. Further studies are needed to confirm our findings and identify the mechanisms involved as well as any prognostic or therapeutic potential.
WuTWFungKPYangCC. Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein better than Trolox. Life Sci. 1994;54:P477‐81.
7.
NovotnýLVítekL. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med. 2003;228:568‐71.
8.
VítekLJirsaMBrodanováM, et al.Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis. 2002;160:449‐56.
9.
SongYSKooBKChoNHMoonMK. Effect of low serum total bilirubin levels (≤0.32 mg/dl) on risk of coronary artery disease in patients with metabolic syndrome. Am J Cardiol. 2014;114:1695‐700.
10.
ChenYHHungSCTarngDC. Serum bilirubin links UGT1A1*28 polymorphism and predicts long-term cardiovascular events and mortality in chronic hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:567‐74.
11.
DjousséLLevyDCupplesLAEvansJCD’AgostinoRBEllisonRC. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol. 2001;87:1196‐200.
12.
HopkinsPNWuLLHuntSCJamesBCVincentGMWilliamsRR. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1996;16:250‐5.
13.
HorsfallLJNazarethIPetersenI. Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort. Circulation. 2012;126:2556‐64.
14.
HuntSCKronenbergFEckfeldtJHHopkinsPNMyersRHHeissG. Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study. Atherosclerosis. 2001;154:747‐54.
15.
KimmHYunJEJoJJeeSH. Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke. 2009;40:3422‐7.
16.
SchwertnerHAJacksonWGTolanG. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem. 1994;40:18‐23.
17.
SchoolingCMKelvinEAJonesHE. Alanine transaminase has opposite associations with death from diabetes and ischemic heart disease in NHANES III. Ann Epidemiol. 2012;22:789‐98.
18.
TemmeEHZhangJSchoutenEGKestelootH. Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control. 2001;12:887‐94.
19.
BreimerLHWannametheeGEbrahimSShaperAG. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem. 1995;41:1504‐8.
20.
TroughtonJAWoodsideJVYoungIS, et al.Bilirubin and coronary heart disease risk in the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Eur J Cardiovasc Prev Rehabil. 2007;14:79‐84.
21.
KunutsorSKBakkerSJGansevoortRTChowdhuryRDullaartRP. Circulating total bilirubin and risk of incident cardiovascular disease in the general population. Arterioscler Thromb Vasc Biol. 2015;35:716‐24.
22.
PageMJMcKenzieJEBossuytPM, et al.Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103‐112.
23.
BrownD. A review of the pubmed PICO tool: using evidence-based practice in health education. Health Promot Pract. 2020;21:496‐498.
24.
StangA. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology. 2010;25:603‐605.
25.
HigginsJPThompsonSGDeeksJJAltmanDG. Measuring inconsistency in meta-analyses. BMJ. 2003;327557‐560.
26.
AjjaRLeeDCSuiXChurchTSStevenNB. Usefulness of serum bilirubin and cardiorespiratory fitness as predictors of mortality in men. Am J Cardiol. 2011;108:1438‐42.
27.
LaiXFangQYangL, et al.Direct, indirect and total bilirubin and risk of incident coronary heart disease in the Dongfeng-Tongji cohort. Ann Med. 2018;50:16‐25.
28.
SuhSChoYRParkMKKimDKChoNHLeeMK. Relationship between serum bilirubin levels and cardiovascular disease. PLoS One. 2018;13:e0193041.
29.
EkblomKMarklundSLJanssonJH, et al.Plasma bilirubin and UGT1A1*28 are not protective factors against first-time myocardial infarction in a prospective, nested case-referent setting. Circ Cardiovasc Genet. 2010;3:340‐7.
30.
EkblomKMarklundSLJohanssonL, et al.Bilirubin and UGT1A1*28 are not associated with lower risk for ischemic stroke in a prospective nested case-referent setting. Cerebrovasc Dis. 2010;30:590‐6.
31.
OdaEKawaiR. A possible cross-sectional association of serum total bilirubin with coronary heart disease and stroke in a Japanese health screening population. Heart Ves. 2012;27:29‐36.
32.
TanakaMFukuiMTomiyasuK, et al.Low serum bilirubin concentration is associated with coronary artery calcification (CAC). Atherosclerosis. 2009;206:287‐91.
33.
VeraTGrangerJPStecDE. Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice. Am J Physiol Regul Integr Comp Physiol. 2009;297:R738‐43.
34.
EndlerGHamwiASunder-PlassmannR, et al.Is low serum bilirubin an independent risk factor for coronary artery disease in men but not in women?Clin Chem. 2003;49:1201‐4.
35.
StockerRYamamotoYMcDonaghAFGlazerANAmesBN. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235:1043‐6.
36.
SeppenJBosmaP. Bilirubin, the gold within. Circulation. 2012;126:2547‐9.
37.
FranchiniMTargherGLippiG. Serum bilirubin levels and cardiovascular disease risk: a Janus Bifrons?Adv Clin Chem. 2010;50:47‐63.
38.
LevinsonSS. Relationship between bilirubin, apolipoprotein B, and coronary artery disease. Ann Clin Lab Sci. 1997;27:185‐92.
39.
WaldenCEKnoppRHJohnsonJLHeissGWahlPWHooverJJ. Effect of estrogen/progestin potency on clinical chemistry measures. The lipid research clinics program prevalence study. Am J Epidemiol. 1986;123:517‐31.
40.
LuquitaMGCataniaVAPozziEJ, et al.Molecular basis of perinatal changes in UDP-glucuronosyltransferase activity in maternal rat liver. J Pharmacol Exp Therapeut. 2001;298:49‐56.
41.
FreemanR. Hormone replacement therapy (estrogen and progesterone): is it necessary for heart disease prevention?Prev Cardiol. 2000;3:21‐4.
42.
YamaguchiTHorioFHashizumeT, et al.Bilirubin is oxidized in rats treated with endotoxin and acts as a physiological antioxidant synergistically with ascorbic acid in vivo. Biochem Biophys Res Commun. 1995;214:11‐9.
43.
YamaguchiTShiojiISugimotoAKomodaYNakajimaH. Chemical structure of a new family of bile pigments from human urine. J Biochem. 1994;116:298‐303.
44.
StenderSFrikke-SchmidtRNordestgaardBGGrandePTybjaerg-HansenA. Genetically elevated bilirubin and risk of ischaemic heart disease: three Mendelian randomization studies and a meta-analysis. J Intern Med. 2013;273:59‐68.
45.
BosmaPJvan der MeerIMBakkerCTHofmanAPaul-AbrahamseMWittemanJC. UGT1A1*28 allele and coronary heart disease: the Rotterdam Study. Clin Chem. 2003;49:1180‐1.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
